What is the role of circulating tumor DNA (ctDNA) testing in patients who have already been diagnosed with cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Role of Circulating Tumor DNA Testing in Patients with Cancer

Circulating tumor DNA (ctDNA) testing serves as a valuable complementary tool when tissue biopsy is unavailable or insufficient, primarily for identifying actionable mutations and monitoring treatment response, though tissue biopsy remains the gold standard for comprehensive molecular profiling and histologic assessment.

Primary Diagnostic Setting

When Tissue is Unavailable or Insufficient

ctDNA testing is recommended as an alternative when tissue samples are inadequate, insufficient, or missing for molecular profiling 1. This is particularly relevant in:

  • Lung cancer (NSCLC): ctDNA can identify EGFR mutations in exons 18-21, RET mutations, and NTRK fusions when tissue is not available or when faster results are clinically required 1, 2, 3
  • Thyroid cancer: The ESMO Precision Medicine Working Group recommends ctDNA for BRAF V600E, RET mutations, and NTRK 1/2/3 fusions if tissue is unavailable or rapid turnaround is needed 2

Critical Limitations at Diagnosis

Negative ctDNA results must be interpreted with extreme caution due to high false-negative rates 1. Approximately 25% of NSCLC patients are "non-shedders" whose tumors release insufficient DNA below detection limits 1. Additionally:

  • ctDNA cannot provide histologic diagnosis, which remains essential 1
  • Limited sensitivity for detecting amplifications (e.g., MET amplification) and fusions compared to tissue NGS 1
  • Cannot identify histologic transformations (small-cell transformation, squamous transformation, EMT) 1

Resistance and Disease Progression Setting

Identifying Resistance Mechanisms

When patients progress on targeted therapy and tissue rebiopsy is not feasible, ctDNA testing can identify specific resistance mechanisms 1. Key applications include:

  • EGFR T790M detection: In NSCLC patients progressing on first- or second-generation EGFR TKIs, ctDNA can identify T790M mutations that predict sensitivity to third-generation TKIs 1, 3, 1
  • Maintaining sensitizing mutations: EGFR-mutant patients typically retain the original sensitizing mutation during progression; absence of both sensitizing and resistance mutations suggests inadequate ctDNA levels rather than true negativity 1

When to Proceed with Tissue Biopsy

Tissue biopsy is mandatory when ctDNA shows negative or low variant allelic frequency (VAF) of sensitizing mutations 1. Low VAF of the sensitizing EGFR mutation correlates with high false-negative rates for T790M testing 1.

At disease progression requiring treatment change, tissue biopsy is recommended to assess all actionable resistance mechanisms, including histologic transformation, which ctDNA cannot detect 1.

Treatment Monitoring and Prognostication

Monitoring Treatment Response

ctDNA demonstrates emerging utility for monitoring treatment response and predicting relapse, though clinical utility of early progression detection remains unproven 1. Evidence shows:

  • Early ctDNA clearance: ctDNA negativity during treatment correlates with longer progression-free survival (PFS) and overall survival (OS) 4
  • Dynamic changes: Significant decreases in maximum somatic allele frequency (MSAF) at best response timepoints predict better outcomes 4
  • Rising ctDNA: Increasing ctDNA levels predict subsequent progressive disease before radiologic changes 4

Prognostic Value

Baseline ctDNA positivity independently predicts worse survival outcomes across multiple cancer types 4, 5, 6, 7, 8. Specifically:

  • In metastatic colorectal cancer, baseline ctDNA burden and early clearance function as prognostic biomarkers 4
  • In advanced endometrial carcinoma, baseline ctDNA positivity associates with poorer PFS (median 1.81 vs 7.39 months) and OS (10.3 vs 24.7 months) 7
  • In hepatocellular carcinoma post-curative treatment, postoperative ctDNA positivity predicts shorter RFS (HR 4.48) and worse OS (HR 2.99) 8

Advantages Over Traditional Protein Biomarkers

ctDNA provides greater cancer specificity and sensitivity compared to standard protein biomarkers 5. In colorectal cancer, ctDNA is superior to CEA in detecting residual disease and early recurrence; in breast cancer, ctDNA outperforms CA 15-3 for detecting early recurrences 5. ctDNA also has a shorter half-life in plasma, allowing real-time assessment of treatment response 5.

Complementary Role with Tissue Analysis

ctDNA and tissue analyses provide complementary rather than redundant information 1. The key advantage of ctDNA is better representation of tumor heterogeneity in progressive disease, as it samples DNA from multiple metastatic sites simultaneously 1. However, tissue remains essential for:

  • Histologic transformation assessment (SCLC, squamous, sarcomatoid) 1
  • Accurate detection of MET amplification (FISH may be superior) 1
  • Comprehensive fusion detection 1
  • Initial histologic diagnosis 1

Special Considerations

CNS Malignancies

For leptomeningeal metastases, CSF-based ctDNA and circulating tumor cell (CTC) detection show enhanced diagnostic sensitivity compared to CSF cytology 9. CSF ctDNA may be more abundant than plasma ctDNA for CNS malignancies and can identify actionable targets and resistance mechanisms 9.

Technical Requirements

Laboratories must deploy assays with adequate analytical sensitivity 3. For EGFR T790M detection in resistance settings, assays should detect mutations in as little as 5% of viable cells 3. Technologies capable of identifying all relevant mutations in target exons should be used 1.

Reporting Standards

ctDNA test reports must include comprehensive pre-analytical variables, assay specifications, and quality metrics 10. Essential elements include:

  • Date of blood collection, analysis, and reporting 10
  • Type of collection tube and storage conditions 10
  • Limit of detection (LOD), limit of quantification (LOQ), and analytical sensitivity/specificity 10
  • cfDNA quantity (ng/mL plasma) and integrity 10
  • Clear indication when quality metrics fail to meet requirements 10

Current Limitations and Future Directions

The clinical utility of ctDNA monitoring for early progression detection has not been demonstrated in randomized trials 1. Therefore, routine monitoring should be restricted to clinical trials or selected cases by tumor boards 1.

ctDNA measurements are more expensive, less widely available, have longer turnaround times, and are less standardized than protein biomarkers 5. However, ongoing developments include integration with tissue data, serial monitoring for minimal residual disease, and methylation-based biomarkers 11.

References

Related Questions

When is the Signatera (circulating tumor DNA) test used in patients with a history of solid tumors, such as colorectal, breast, or lung cancer?
What is Tempus (Temporal) circulating tumor (ct) DNA?
What screening and preventive interventions are recommended for a male who was sexually assaulted by another male eight months ago?
In a diabetic patient with a diabetic foot ulcer, how frequently can cadexomer‑iodine dressings be applied?
In a 15‑year‑old adolescent with a known spongy kidney who now has impaired renal function (rising serum creatinine), elevated urea, and elevated C‑reactive protein, and who has not responded to a 500 mL isotonic fluid bolus, what is the appropriate next step in management?
What is the appropriate diagnosis for fluid overload?
Based on the BAARS‑IV assessment scores (high inattentive and sluggish cognitive tempo symptoms, borderline hyperactivity/impulsivity, symptom onset at age 10), what is the appropriate diagnosis for this patient?
What dose of nitrofurantoin (Macrobid) can be administered to a hospice patient who cannot leave an extended care facility for IV therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.